^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    RarePlex® ARv7/Synaptophysin CTC Panel Kit

    Company:
    RareCyte
    Type:
    Laboratory Developed Test

    Details

    Evidence
    News
    RareCyte’s androgen receptor splice variant 7 (ARv7) and neuroendocrine marker, synaptophysin (SYP), circulating tumor cell assay provides highly accurate, repeatable, and precise results for circulating tumor cell count, ARv7 and SYP biomarker expression, and is suitable for use in large, multi-center clinical trials of prostate cancer. ARv7/Synaptophysin assay enables a blood-based investigation of two prominent mechanisms by which tumors become resistant to second line endocrine therapies.
    Cancer:
    Prostate Cancer
    Gene:
    AR (Androgen receptor), SYP (Synaptophysin)
    Method:
    Liquid biopsy